Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2021.2228
Abstract: Importance It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Objective To assess the safety and efficacy of ticagrelor vs prasugrel… read more here.
Keywords: ticagrelor; analysis; group; randomized clinical ... See more keywords
Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-017-1579-9
Abstract: According to guidelines, it is recommended to give P2Y12 inhibitors (preferably ticagrelor or prasugrel) at the time of first medical contact in patients with STEMI. However, in real life antiplatelet treatment strategies are different among… read more here.
Keywords: ticagrelor prasugrel; registry; p2y12 inhibitors; p2y12 ... See more keywords
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y12 inhibitors in a large observational study.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2018.09.011
Abstract: BACKGROUND To compare the prescription rates, safety, and efficacy of contemporary P2Y12 inhibitors in acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI). METHODS From 9684 ACS patients who underwent PCI in a nationwide,… read more here.
Keywords: ticagrelor prasugrel; acute coronary; prescription rates; p2y12 inhibitors ... See more keywords
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.01.027
Abstract: Ticagrelor is a nonthienopyridine direct and reversible P2Y12 platelet receptor antagonist, and unlike prasugrel or clopidogrel inhibits, at least partially, the sodium-independent equilibrative nucleoside transporter 1 [(1)][1]. This ticagrelor-mediated off-target effect has potential to improve read more here.
Keywords: prasugrel; clopidogrel steady; prasugrel clopidogrel; ticagrelor prasugrel ... See more keywords
COMPARISON OF BLEEDING RATES AND CLINICAL OUTCOMES BETWEEN TICAGRELOR AND PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A PROPENSITY SCORE-MATCHED ANALYSIS
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)34404-2
Abstract: Background: In acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI), ticagrelor or prasugrel are increasingly used, but limited data are available on the safety and efficacy of ticagrelor vs. prasugrel use in real… read more here.
Keywords: prasugrel; ticagrelor prasugrel; acute coronary; percutaneous coronary ... See more keywords
Infarct size following loading with ticagrelor/prasugrel versus clopidogrel in ST-segment elevation myocardial infarction
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.1732
Abstract: Treatment with newer direct-acting anti-platelet drugs (Ticagrelor and Prasugrel) prior to primary percutaneous coronary intervention (PCI) is associated with improved clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI) when compared with Clopidogrel. We… read more here.
Keywords: ticagrelor prasugrel; clopidogrel; infarct size;
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction
Sign Up to like & getrecommendations! Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2017-312534
Abstract: Objective To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions. Methods Case-referent study using the Pharmacoepidemiological General Research eXtension (PGRx)-acute coronary syndrome (ACS) registry. Cases were… read more here.
Keywords: ticagrelor prasugrel; new antiplatelets; myocardial infarction; clopidogrel ... See more keywords
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Interventional Cardiology"
DOI: 10.1155/2023/1147352
Abstract: Background Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial. Our objective was to compare the safety… read more here.
Keywords: ticagrelor prasugrel; p2y12; clopidogrel; real world ... See more keywords
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
Sign Up to like & getrecommendations! Published in 2021 at "Circulation: Cardiovascular Interventions"
DOI: 10.1161/circinterventions.120.009434
Abstract: Supplemental Digital Content is available in the text. Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed… read more here.
Keywords: ticagrelor prasugrel; prasugrel; clopidogrel; cyp2c19 genotype ... See more keywords
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk
Sign Up to like & getrecommendations! Published in 2022 at "Circulation: Cardiovascular Interventions"
DOI: 10.1161/circinterventions.122.012204
Abstract: Background: The relative efficacy and safety of more potent P2Y12 inhibitors in patients with acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary intervention remains unclear. We aimed to study the treatment effect… read more here.
Keywords: coronary syndrome; prasugrel; ticagrelor prasugrel; acute coronary ... See more keywords